| Literature DB >> 17270437 |
Harold Mastalerz1, Ming Chang, Ping Chen, Pierre Dextraze, Brian E Fink, Ashvinikumar Gavai, Bindu Goyal, Wen-Ching Han, Walter Johnson, David Langley, Francis Y Lee, Punit Marathe, Arvind Mathur, Simone Oppenheimer, Edward Ruediger, James Tarrant, John S Tokarski, Gregory D Vite, Dolatrai M Vyas, Henry Wong, Tai W Wong, Hongjian Zhang, Guifen Zhang.
Abstract
Novel C-5 substituted pyrrolotriazines were optimized for dual EGFR and HER2 protein tyrosine kinase inhibition. The lead compound exhibited promising oral efficacy in both EGFR and HER2 driven human tumor xenograft models. It is hypothesized that its C-5 morpholine side chain binds in the ribose phosphate portion of the ATP binding pocket.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17270437 DOI： 10.1016/j.bmcl.2007.01.002
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823